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Abstract
Background: Migraine is a chronic neurologic disease that can severely affect the patient's quality
of life. Although in recent years many randomised studies have been carried out to investigate the
effectiveness of acupuncture as a treatment for migraine, it remains a controversial issue. Our aim
is to determine whether acupuncture, applied under real conditions of clinical practice in the area
of primary healthcare, is more effective than conventional treatment.
Methods/Design:  The design consists of a pragmatic multi-centre, three-armed randomised
controlled trial, complemented with an economic evaluation of the results achieved, comparing the
effectiveness of verum acupuncture with sham acupuncture, and with a control group receiving
normal care only.
Patients eligible for inclusion will be those presenting in general practice with migraine and for
whom their General Practitioner (GP) is considering referral for acupuncture. Sampling will be by
consecutive selection, and by randomised allocation to the three branches of the study, in a
centralised way following a 1:1:1 distribution (verum acupuncture; sham acupuncture; conventional
treatment). Secondly, one patient in three will be randomly selected from each of the acupuncture
(verum or sham) groups for a brain perfusion study (by single photon emission tomography). The
treatment with verum acupuncture will consist of 8 treatment sessions, once a week, at points
selected individually by the acupuncturist. The sham acupuncture group will receive 8 sessions, one
per week, with treatment being applied at non-acupuncture points in the dorsal and lumbar regions,
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using the minimal puncture technique. The control group will be given conventional treatment, as
will the other two groups.
Discussion: This trial will contribute to available evidence on acupuncture for the treatment of
migraine. The primary endpoint is the difference in the number of days with migraine among the
three groups, between the baseline period (the 4 weeks prior to the start of treatment) and the
period from weeks 9 to 12. As a secondary aspect, we shall record the index of laterality and the
percentage of change in the mean count per pixel in each region of interest measured by the brain
perfusion tomography, performed on a subsample of the patients within the real and sham
acupuncture groups.
Trial registration: Current Controlled Trials ISRCTN98703707.
Background
Headache, which is one of the most common causes of
patients' seeking attention at neurology clinics, is a highly
prevalent health problem and one with considerable soci-
oeconomic impact [1-4]. In Spain, the prevalence of
migraine is 16.9% among women and 7.4% among men
[5], with 60% of patients having a family background of
such headaches [6]. This epidemiologic profile is similar
to that reported for other countries [7]. Headache can be
considered a social pathology, as it is often discapacitat-
ing. A population based study in the USA found that most
of the cost provoked by headaches was related to days off
work and loss of productivity [8]. It has been estimated
that routine activities are limited during 78% of migraine
attacks [9]. Spain is believed to lose 13 million working
days every year because of migraine [10], and its direct
and indirect costs amount to 1076 million Euros, of
which 65% is accounted for by indirect costs [5].
There is no curative treatment for migraine, but there do
exist various options for pharmacological treatment, and
the choice of one type or another depends on the fre-
quency of the attacks, their severity, the patient's activity
and tolerance to side effects. In Spain it has been esti-
mated that the most common treatment is applied at the
moment of the attack (86.6%); the drugs used when a
severe attack occurs include non steroidal anti-inflamma-
tory drugs (NSAIDs) (36.7%), tryptans (28.4%), paraceta-
mol (7.7%) and ergotamine derivatives (7.7%). Patients
who suffer repeated attacks are recommended the prophy-
lactic administration of medication such as beta blockers,
tricyclic antidepressants and antiepileptic drugs [11]. The
effectiveness of these treatments, although it has been cor-
roborated by numerous studies, is limited. For severe
cases, it has been estimated that one third of patients fail
to respond to the administration of tryptans, which more-
over are reserved for those patients who suffer the most
severe attacks or who been found to respond poorly to
NSAIDs. Prophylactic treatment reduces the frequency of
attacks by 50%, but requires a gradual increase of the dose
applied and it has an objectifiable benefit of 6 months.
Prophylaxis, therefore, reduces but does not eliminate the
problem and the need for medication against severe
attacks [12]. Tolerance to pharmacological treatment is
limited, both for therapy for severe cases and for preven-
tive measures. The main side effects in the former case are
gastrointestinal disorders (with NSAIDs) or cardiovascu-
lar problems (with ergotamine substances and tryptans).
Among the side effects arising from chronic treatment are
sedation, fatigue, lack of tolerance to exercise, and weight
gain. In addition, there are physiological factors such as
pregnancy or old age, and pathological ones such as
asthma, ischemic heart disease or hypertension, for which
the administration of some of these drugs is contraindi-
cated, and this circumstance also affects the applicability
of the therapy in clinical practice [12].
Acupuncture is widely used to treat headache, and can be
applied as the sole therapy or as part of a more complex
treatment programme [13,14]. Despite its popularity,
there persists some controversy as to the differentiation
between the specific and the nonspecific effects of acu-
puncture. A Cochrane review published in 2001 [15] con-
cluded that, in general terms, current evidence supports
the value of acupuncture as a treatment for idiopathic
headaches, but due to clinical heterogeneity and the low
methodological quality of the 26 studies included, it was
not possible to make direct recommendations for clinical
practice. Fundamentally, some forms of acupuncture
seem to be beneficial, but it is unclear as to which treat-
ment strategies (acupuncture points, type of stimulation,
frequency, etc.) should be favoured.
The three most recent studies published, during the last
two years, report conflicting results. Two studies, which
can be classified as belonging to the German strategy of
assessing the coverage of acupuncture for certain proc-
esses, concluded that both verum acupuncture and sham
acupuncture (superficial acupuncture at points not con-
sidered to be acupuncture points) are more effective than
remaining on the waiting list, untreated [13], but that
their results did not differ significantly from thoseBMC Complementary and Alternative Medicine 2008, 8:12 http://www.biomedcentral.com/1472-6882/8/12
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obtained by pharmacological treatment [16]. The third
study was a pragmatic one that concluded that acupunc-
ture produces a clinically significant improvement in
patients suffering chronic headache, especially in the case
of migraine, compared with conventional treatment;
moreover, it leads to decreased consumption of medica-
tion, visits to the GP and days off work [14]. Endres et al.,
in a recent review of the subject, concluded that acupunc-
ture treatment for 6 weeks is not inferior to preventive
pharmacological treatment for 6 months, but that the use
of acupuncture at specific points, needle stimulation and
the depth of the puncture are not as important as had pre-
viously been thought [17].
The single photon emission computed tomography
(SPECT) of brain perfusion is a technique that obtains
three-dimensional images of the cerebral distribution of a
radiopharmaceutical, reflecting regional brain perfusion
[18,19]. SPECT is less expensive than other techniques, is
more widely available and is of more general clinical
application; moreover, it may enable a semiquantitative
analysis of the images [20]. Numerous studies have been
made of regional cerebral blood flow (rCBF) in patients
with migraine, and hypoperfusion has been found in
many cases, with asymmetries in others [21-27]. Indeed,
some authors have correlated the abnormalities observed
with the severity of the attack [25]. Few studies have made
use of brain perfusion SPECT to examine the effects of
acupuncture. Lee et al. studied the cerebrovascular
response to traditional acupuncture among patients suf-
fering an obstruction of the middle cerebral artery, and
compared the results obtained with those produced
among 8 healthy volunteer control subjects. Among the
patients, there were focal increases in rCBF in the hyper-
perfused regions that surrounded the ischemic injury, and
also in the ipsilateral or contralateral sensory-motor cor-
tex, while the controls presented multiple sites with raised
rCBF in each hemisphere, thus showing that among the
patients acupuncture produced an activation of neurons
that are viable and undergoing cerebral reorganization
[28]. Wang and Jia studied the effects of acupuncture on
the rCBF of 9 patients with cerebrovascular disease, and
on that of 11 healthy subjects, finding significant differ-
ences in the cerebral cortex and the contralateral thala-
mus, in the ipsilateral basal ganglia and in the cerebellum
[29]. Newberg et al. investigated changes in rCBF associ-
ated with the analgesic effect of acupuncture in 7 patients
with chronic pain, and compared these effects with those
found in 5 healthy controls. Baseline studies of the thala-
mus of patients suffering pain presented significant asym-
metries, in comparison with the controls. This asymmetry
became normalized or inverted after acupuncture. These
authors also found significant correlations with changes
in the activity of the prefrontal cortex and in the sensory-
motor ipsilateral area [30]. Ha-Kawa et al. described the
changes in rCBF induced by acupuncture among 3
patients with dystonia, and related these changes to the
action of acupuncture on the central nervous system [31].
Acupuncture produces complex changes in the areas of
the brain concerned with pain transmission and percep-
tion, although the specific details of these effects have yet
to be established. The use of neuroimaging techniques
enables us to observe changes in cerebral cortical per-
fusion related to the type of acupuncture applied (verum
or sham), and to determine the existence of specific or
nonspecific patterns of cortical activation [32].
Summing up, the disparity in results obtained, depending
on how the technique is applied, on the diverse therapeu-
tic strategies possible with acupuncture, and on the need
to attempt to measure the specific and the nonspecific
effects of the technique, led us to design this randomised
controlled pragmatic study aimed at investigating the
effectiveness of acupuncture applied in primary health-
care centres for patients suffering migraine. Our goals are:
a) to assess the effectiveness and safety of acupuncture in
the context of standard clinical practice; b) to derive an
economic evaluation of the technique; c) to determine the
specific and nonspecific effects of the intervention in the
study; and d) to examine changes in brain perfusion using
SPECT tomography to examine the consequences of the
different interventions.
Methods
Design
Randomised controlled multicentre pragmatic study, with
three arms, to compare the effectiveness of the individual-
ized active acupuncture (Group A), minimal acupuncture
(in locations not corresponding to acupuncture points, in
different metamers and at a depth of less than 3 mm)
(Group B) and conventional treatment (Group C). The
patients will be blinded to the two acupuncture treat-
ments. These patients will be assessed and the results ana-
lysed by professionals blinded with respect to the
allocations of the different treatments. A stratified ran-
domised subsample of groups A and B will be given a
SPECT tomography in order to determine possible
changes in the cerebral vascular flow provoked by the two
different types of acupuncture applied. The duration of
the study, per patient, will be 28 weeks, four of which will
be prior to randomisation (baseline), followed by 8 weeks
of treatment and then 16 weeks' follow up.
Study period
January 2008-December 2010
Study subjects
General practitioners at the three primary healthcare clin-
ics taking part in the study, belonging to the public health-BMC Complementary and Alternative Medicine 2008, 8:12 http://www.biomedcentral.com/1472-6882/8/12
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care system in Andalusia (at Armilla, Valle de Lecrín and
Ugíjar, all in the province of Granada), will identify
potentially eligible patients with migraine symptoms. An
independent assessor will interview the participants, per-
form the screening and instruct the patients in how to
complete the headache diary (to be filled in over a period
of 4 weeks). The patients will be informed about the pro-
cedures of the study and will be requested to sign the
informed consent form. They will also be informed about
the possible risks associated with the different types of
acupuncture (infection, fainting, bruising) and told that
that they may end their participation in the study at any
time, with no type of penalty or loss of benefits to which
they would otherwise be entitled. Although only a sub-
sample will be given the SPECT diagnostic test, all the
patients included in the study will be required to sign their
informed consent to this test.
The patients included must be at least 18 years old, diag-
nosed with migraine, in accordance with the principles of
the International Headache Society [1] and the recom-
mendations for clinical trials published by the same Soci-
ety [33], with or without aura, with a frequency of
migraine attacks of 2–6 times per month, with a mini-
mum chronicity of one year, the onset of symptoms at an
age of less than 50 years, having completed the headache
diary, and have signed their informed consent. Criteria for
exclusion will include acupuncture during the 12 previous
months, incapacity to distinguish between tensional
headache and migraine, secondary headaches, contraindi-
cation to acupuncture (pregnancy, generalised dermopa-
thy, treatment with anticoagulants, thrombocytopenia) or
to the performance of SPECT techniques (cerebrovascular
accident, traumatic brain injury, alcohol or drug abuse,
severe psychiatric disorders) and inability to complete the
questionnaires or to reply to the assessor's questions.
The ethical validity of this study has been assessed and
approved by the Andalusian Regional Committee for
Clinical Trials, following approval by the Research Com-
mittee corresponding to each of the participating centres.
The study design complies with the fundamental princi-
ples set out in the Helsinki Declaration, as revised in
Tokyo (2004), as well as those of the Council of Europe
Convention on human rights and biomedicine, and the
requirements of Spanish law regarding the field of bio-
medical research, the protection of personal data, and
bioethics. All patients must sign the form of informed
consent to clinical research procedures. During the course
of the study, audits will be carried out as considered nec-
essary by the corresponding Committee for Research Eth-
ics and by the Quality Control Committee responsible for
the centre in question, these being independent of any
external audits (by the source of research funding) that
may be required.
Randomisation and treatment allocation
Sampling will be by consecutive selection, in accordance
with inclusion-exclusion criteria, over a period of 24
months until the predetermined sample size has been
obtained. Randomised allocation to the three arms of the
trial will be carried out using an appropriate computer
program (EpiDat v 3.1), in a centralised way (by the
Research Unit at Hospital Costa del Sol, Malaga), follow-
ing a 1:1:1 distribution (verum acupuncture: minimal
acupuncture: conventional treatment), with a sequence
for each clinic in blocks of 9. Secondarily, one patient in
three will be randomly selected from each of groups A and
B to be given a SPECT brain perfusion study. Neither the
centres nor the doctors participating in the trial will take
part in the randomisation procedure, and the sequence of
the latter will remain concealed until the completion of
the trial. The patients who fulfil the criteria for inclusion
and who give their informed consent will be included in
the trial. After each patient's inclusion, his/her GP will
contact the randomisation centre, where the patient will
be registered, and the doctor will be told, by phone and by
fax, which of the three arms of the trial the patient has
been allocated to. This procedure guarantees that the ran-
domisation process will not be influenced by the doctor
participating. We shall endeavour to ensure that all partic-
ipants begin the trial with the same expectations of effec-
tiveness; accordingly, the initial information provided to
the patient will state that all the treatments provided in
the course of the trial are effective [13,14,16].
Criteria and procedure for withdrawal of patients from the 
trial
A patient may be withdrawn from the trial at any time, at
his/her own discretion or at that of the researcher. The rea-
sons for interrupting the patient's participation in the trial
will be recorded on the summary page of the Data Record
Book (DRB). If there is any suspicion of secondary head-
ache or of a malignant pathology, as well as the patient
being withdrawn from the trial, he/she will be referred to
his/her GP so that a conclusive diagnosis may be made on
the basis of relevant complementary tests, or so that refer-
ral to a neurologist may be considered.
Sample size
In calculating the sample size, we assumed a power of
90% and α value of 5%, in order to detect a difference of
1.6 days with migraine with a standard deviation of 2.8
days; this implies a sample size of 72 per group in a design
with three equal groups. We propose to recruit 270
patients in order to allow for a 20% withdrawal rate.
Interventions
The treatment strategies with verum and with sham acu-
puncture were developed by means of consensus with
experienced acupuncture practitioners. All the patientsBMC Complementary and Alternative Medicine 2008, 8:12 http://www.biomedcentral.com/1472-6882/8/12
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will be allowed to take symptomatic medication to treat
headache episodes if necessary, and to continue taking the
medication to prevent migraine attacks, following their
GPs' recommendations and those of the Headache Study
Group of the Spanish Neurological Society [34].
The two groups will receive a total of 8 acupuncture ses-
sions (at a rate of 1 session per week), each lasting 30 min-
utes, comprising the technique described below and at the
locations specified. The acupuncture needles will be ster-
ile, single-use, model S-J2030, made by Seirin Corpora-
tion (Shizuoka, Japan) in accordance with EC regulations.
A) Verum acupuncture
Individualized treatment on the basis of diagnosis in
accordance with traditional Chinese medicine (TCM),
which the acupuncture physician may modify in accord-
ance with the evolution of the patient's symptoms. The
TCM diagnosis, evolution, points and techniques applied
should be recorded in the DRB.
The doctors responsible for the treatment (specialists in
acupuncture with a minimum training of 600 hours and a
mean experience of 5.7 years) will insert sterile, single-use
filiform acupuncture needles, with a length of 10–30 mm
and a diameter of 0.20 mm, with the aid of a guide tube
at each of the points, after first disinfecting the skin and
with the patient in decubitus. The puncture will be made
in accordance with the standards of TCM, to a depth of 1–
3 cm, depending on the points selected. The insertion will
be followed by stimulation performed with bidirectional
rotation actions of the needle sheath in order to produce
the sensation known as Deqi, commonly described as a
sensation of irradiation. The needle will be maintained in
place for 30 minutes, with 1–3 manipulations per session.
Any adverse reaction or side effect should be recorded in
the DRB, with a detailed description, and stating the date
of occurrence.
The time dedicated to the patients allocated to each of the
groups should be identical. Similarly, the same time
should be devoted to pre and post session evaluations.
The patients randomly selected for the SPECT diagnostic
test will be given their first session at the Nuclear Medicine
Department of the Virgen de las Nieves Hospital. The
remaining sessions, as well as those applied to the other
patients, will be performed at the healthcare centres par-
ticipating in the trial.
B) Sham acupuncture
The patients who are randomly assigned to this group will
be given minimal acupuncture (the real insertion of acu-
puncture needles, to a depth of less than 3 mm) at 5 bilat-
eral non-acupuncture points located 1.5 cm from the
mean dorsal line and lumbar curve, specifically, at the spi-
nal apophysis of the T10, T11, T12, L1 and L3 vertebrae.
The technique will not differ at all from that used for
Group A, except that no attempt will be made to produce
the Deqi sensation.
C) Conventional treatment
The patients will be given the conventional treatment pre-
scribed by their GP.
Brain perfusion tomography (SPECT)
Preparation
▪ During the 24 hours prior to the examination, the
patient must not consume coffee, colas, energy drinks,
alcohol, tobacco or any drugs that might affect the cere-
bral blood flow.
▪ The procedure will be explained to the patient and his/
her capacity to collaborate in the performance of the
examination will be assessed.
Criteria for exclusion
Patients will be excluded from the trial if they are lactating
or have a case history suggesting possible alterations to
brain perfusion patterns in the SPECT test (such as cere-
brovascular accident, traumatic brain injury, alcohol or
drug abuse, or severe psychiatric disorders).
Radiopharmaceuticals
The radiopharmaceutical used will be 99mTc-ECD (Neu-
rolite, Bristol-Myers Squibb Pharma Belgium Sprl). The
manufacturer's instructions will be followed for reconsti-
tution and labelling of the product. The dose given to each
patient will be measured using an activimeter (Capintec
CRC-35R, Cleveland Ohio USA) immediately following
intravenous administration of the radiopharmaceutical.
Its quality will be controlled in accordance with the
method described by the manufacturer, to achieve at least
the recommended radiochemical purity of 90%.
Gammacamera
In carrying out the examination, we will use a triple-head
gammacamera (Picker Prism 3000, Cleveland Ohio USA),
equipped with collimators for a low-energy and ultra
high-resolution neuro-fan beam (Leuhr-NeuroFan), con-
nected to a Picker Odyssey FX image processing worksta-
tion.
Procedure
▪ Baseline or pre-acupuncture trial:
￿ With the patient in decubitus, eyes open and ears un-
occluded, administer 260 MBq (7 mCi) of 99mTc-ECDBMC Complementary and Alternative Medicine 2008, 8:12 http://www.biomedcentral.com/1472-6882/8/12
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intravenously, with the vein canalized at least 10 minutes
previously.
￿ Image acquisition will begin 20 minutes following the
injection of the radiopharmaceutical, in accordance with
the following parameters: 360° circular orbit, rotation
radius of 12.9 cm, step and shoot mode (3°/40 sec/step),
128 × 128 matrix, no zoom, and an energy window of 140
± 20 KeV. Total acquisition time, 45 minutes.
￿ After this initial image acquisition, the patients will be
given the first acupuncture session (verum or sham),
under the following procedure:
1. Group A: verum acupuncture at LI4 and LIV3 (these
points were decided upon by consensus among the acu-
puncture physicians taking part in the trial, and because
they are the ones most frequently employed in treating
primary headache [35]). The insertion will be followed by
stimulation performed with bidirectional rotation actions
of the needle sheath in order to produce the Deqi. The nee-
dle will be maintained in place for 30 minutes, with 1–3
manipulations per session.
2. Group B: sham acupuncture at two bilateral points,
located 1.5 cm from the spinal apophysis of the T12 and
L1 vertebrae, at a depth of less than 3 mm. The technique
will not differ at all from that used for Group A, except
that no attempt will be made to produce the Deqi sensa-
tion.
▪ Post-acupuncture trial:
￿ 5 minutes before ending the acupuncture session,
administer 925 MBq (25 mCi) of 99mTc-ECD intrave-
nously. Image acquisition will begin approximately 30
minutes later, using the same acquisition protocol and
with a total acquisition time of 20 minutes.
▪ Post-treatment trial:
￿ This will be performed at week 12 after randomisation.
￿ This trial will be carried out with the same dose of radi-
opharmaceuticals and under acquisition conditions iden-
tical to those of the post-acupuncture study.
Image processing and analysis
For image reconstruction, will be used a filtered backpro-
jection algorithm, using Low-Pass filter Butterworth type
(6.0 and a cutoff frequency of 0.3), and attenuation cor-
rection by Chang's method with an attenuation coeffi-
cient of 0.11 cm-1. After reconstruction imaging is
reoriented in cross sectional planes according orbito-
meatal axis (transaxial, saggital and coronal) for study
comparison. Imaging will be evaluated both qualitatively
and semi-quantitatively. For visual assessment, the cross-
sections will be summed two by two. In the semi-quanti-
tative analysis, they will be summed five by five.
The "Brain Ratios" program will be employed for semi-
quantitative image analysis. This program enables us to
plot and locate elliptical, rectangular or irregular regions
of interest (ROI) in the cerebral cortex, automatically,
interactively or manually. It is also possible to apply ROI
that have been stored from previous studies. The location
and size of the different ROI can be modified, if necessary.
In the semi-automatic method, the operator selects a
transaxial image that is reoriented in the orbital-meatal
plane, centred on the central grey matter, and draws an
ellipse to outline the external borders of the cerebral cor-
tex. Then, within the ellipse, the program identifies 12
regions in the right cerebral hemisphere and 12 symmetric
regions in the left cerebral hemisphere.
The following regions are specified: superior, middle and
inferior frontal, anterior cingulated, inferior, middle and
superior temporal, posterior/precuneous cingulated, tha-
lamus, cerebellum, occipital cortex and left and right
hemispheres, as well as the whole brain. The advantage of
using this method is that it is not operator dependent. The
program determines the number of pixels, the total counts
and the activity normalized by surface (pixel of each ROI).
It also determines the indices of the total counts and of the
mean number of counts per pixel among each precise ROI
and another one used as reference (left and right hemi-
sphere, cerebellum, occipital cortex). The values for the
regional brain perfusion in the post-acupuncture study
will be obtained by calculating the number of total counts
in each ROI, and subtracting from this value the decay-
adjusted total number of counts for the same ROI in the
pre-acupuncture study. The mean number of counts per
pixel in each ROI will be normalized to the activity of the
whole brain.
Results measures
Each patient will fill in a headache diary during the 4 con-
secutive weeks immediately before the trial (baseline
period), and during the 4 weeks following it (see figure 1).
The diaries will be complemented with information on 4
additional weeks, from week 21 to week 24 after randomi-
zation (the follow-up period) Headache severity should
be recorded in the diaries on a 3-point scale, by which 1
represents the presence of mild pain, 2 represents moder-
ate pain and 3, severe pain (with incapacity to carry out
everyday activities or necessity to remain in bed). The
diary will also record the symptomatic and/or prophylac-
tic medication taken, specifying the brand name and the
number of doses. It should be clearly stated on the coverBMC Complementary and Alternative Medicine 2008, 8:12 http://www.biomedcentral.com/1472-6882/8/12
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Trial work plan Figure 1
Trial work plan.
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of the diary that the information contained within it is
confidential. In addition, before starting the treatment,
and also at 12 and 24 weeks after starting it, the patients
will be requested to fill in a questionnaire with sociode-
mographic data and information concerning days off
work because of headache; this will be compiled together
with the Goldberg Anxiety-Depression Scale register and
the results obtained from the Spanish version of the Head-
ache Impact Test [36] and the SF-12 Health Survey (ver-
sion 2). The purpose of this is to evaluate health-related
aspects of the patient's quality of life [37]. The adverse
effects of the techniques under study, and those of any res-
cue medication taken by the patient, will also be recorded.
During the baseline evaluation, the patient will be asked
to provide an anamnesis of the characteristics of the head-
ache, in accordance with the recommendations of the
International Headache Society, in order to classify the
type of headache and to assess the term of the pain. Fol-
lowing this, an anamnesis and examination will be per-
formed in accordance with the norms of traditional
Chinese medicine.
Primary outcome measure
▪ The difference in the number of days with migraine
(DWM) between the baseline period and the period span-
ning weeks 9–12 (DWM1).
Secondary outcome measures
▪ DWM between the baseline period and the period span-
ning weeks 21–24 (DWM2) after randomization.
▪ Change in the health-related quality of life between the
baseline, final and follow-up periods, assessed by the SF-
12 Health Survey.
▪ Days free from pain.
▪ Proportion of patients with at least 50% fewer headaches
during the period spanning weeks 9–12 [33], in compari-
son with the baseline situation.
▪ Days off work, or of incapacity to perform daily activi-
ties.
▪ Change in the consumption of symptomatic/analgesic
and prophylactic medication for migraine attacks, accord-
ing to the patient's record of the name of the drug and the
daily dose consumed, between the baseline period, the
end of treatment and after six months.
▪ Change recorded on Goldberg's Depression/Anxiety
Scale [38] between the baseline period, the end of treat-
ment and after the follow-up period.
▪ Difference in the results of the Spanish version of the
Headache Impact Test [39], the psychometric properties
of which have been proven [36], between the baseline
period, the end of treatment and after the follow-up
period.
▪ SPECT: The following values will be calculated for the
semi-quantitative analysis of the images:
￿ Percentage change of the mean value of counts per pixel
for each region of interest, calculated as follows:
￿ We shall also calculate an index of laterality (IL), as fol-
lows:
Evaluation of treatment credibility
Patients in Groups A and B will be asked, after the fourth
treatment session, four items to be assessed on a continu-
ous analogue visual scale from 0 to 10 (0 = totally disa-
gree; 10 = totally agree): (1) Do you believe this treatment
will reduce the pain you are suffering?; (2) Does the treat-
ment seem to be a logical one?; (3) Would you recom-
mend this treatment to a friend or relative with the same
problem?; (4) Do you believe this treatment could be
applicable to treat other problems? [40,41]
Sociodemographic variables
The following sociodemographic variables will be ascer-
tained: date of birth, sex, marital status, level of education
and race.
Variables related to the severity of the problem, occupational aspects 
and an estimation of direct tangible costs
Duration, in years, of the headache, its frequency, the
duration of each attack and the degree of incapacity pro-
duced by the migraine.
Health utility will be measured in quality-adjusted life
years gained by each patient, calculating the area under
the curve of the SF-12 at 12 weeks after the start of treat-
ment [42]. To estimate the costs of the different treat-
ments, a map of activities will be created, and we will
measure the costs that distinguish them (acupuncture,
conventional treatment). The activities will be evaluated
using an Activity Based Costing approach, according to
which each activity consumes resources (inputs) – per-
sonal, materials and pharmaceutical – in order to produce
results (outputs). These activities will be assessed one by
one. The cost of each therapeutic treatment is defined as
% change
post acupuncture pre acupuncture
pre acupunctu
=×
−
100
r re
IL
right left
right left
=
−
×−
()
() 1
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the sum of the costs of each of the activities that make it
up. Thus we shall obtain a more accurate view of the cost
variation produced by each treatment with respect to
every other one, and will be able to study its impact on the
following subprocess, as well as to make use of this infor-
mation in future studies. The cost components of the
activities addressed and the criteria applied to evaluate
them in financial terms are as follows:
1.  Personal. The consumption of human resources
involved in carrying out the different activities. This eval-
uation includes the cost per hour of each category of pro-
fessional staff. The cost is estimated taking into account
the data provided by the Andalusia Public Health Service
(SSPA), and includes both the explicit cost (wages and sal-
aries paid) and the implicit cost (time travelling to and
from the clinic, the environmental cost of this travelling,
etc.).
2. Occupational. We will record the number of days off
work, or incapacitated for the performance of routine
tasks.
3. Materials. This includes the consumption of materials
required for carrying out each activity. Each such material
cost will be evaluated in accordance with the price
recorded in the corresponding catalogue of the supplies
department/service at the hospital or health district in
question.
4. Pharmaceuticals. We shall consider the costs of the dif-
ferent pharmaceutical products (quantity and unit of
measurement), evaluated in accordance with the normal
price for sale to laboratories.
5. Opportunity cost. This will include the sum of the out-
puts of the potential activities that are not carried out as
the result of applying the treatment, when an alternative
might be used, and will include the potential financial
cost of the resources employed.
On the basis of the ABC approach, the resources imputed
to each patient can be applied, within a multidisciplinary
table based on a modular matrix to act in the manner of a
'meter' for each patient, to the analysis model and thus we
obtain the SF-12 curve showing the variation in the
patient's quality of life and the potential cost savings for
the public healthcare system, together with the increased
years of life attained for each patient.
Characteristic diagnostic variables according to traditional Chinese 
medicine
The acupuncture physicians participating in the trial will
be required to record the information needed to make a
diagnosis according to traditional Chinese medicine,
including the following factors: (1) the location of the
headache; (2) the meridian or meridians most likely to be
involved; (3) internal factors such as Blood, Qi, Yin, Yang,
etc.; (4) external pathogens such as Wind, Phlegm, Cold,
etc.; (5) the internal organs affected; (6) the state of inter-
nal body functions such as Stagnation, Excess, or Defi-
ciency.
Data compilation and analysis
Data compilation
A referral form has been drawn up, to be filled in by the
GP requesting inclusion in the trial of patients who fulfil
the selection criteria. A data base will be designed for the
electronic storage of the variables recorded in the purpose-
built (physical) data record book (DRB). This database
(CRDD) will be kept at the analysis centre (in the
Research Support Unit, Hospital Costa del Sol, Marbella.
Malaga), which will be independent of the randomisation
section. Each participating centre will have a duplicate of
the structure of the CRDD, together with a codebook con-
taining the definitions and operative characteristics of all
the variables. This information will be compiled within
an overall file containing the data for all the variables
addressed in this trial, both in the user-controlled formats
and in those determined by direct observation. These data
will be recorded weekly in the CRDD and sent, in coded
form, to the analysis centre for safekeeping. Neither the
DRB nor the CRDD will identify the group to which the
patient is allocated. This information will be controlled by
the physician carrying out the treatments, and who will be
responsible for liaising with the randomization centre. An
external assessor will record all the information except
that which is reserved for the medical staff, and will man-
age all aspects of the distribution of the patients; neverthe-
less, this assessor will be blind, at all times, to the
treatment actually given to each patient. Every two weeks,
the analysis centre will perform a quality control exercise
on the data received.
Monitoring data and side effects
Records will be kept of all side effects that are reported,
and possible adverse events caused by the experimental
treatment or the medication provided.
Statistical analysis
Two types of population will be analysed: (1) population
per intention to treat (ITT), with all the patients ran-
domised; (2) population per protocol (PP), including
only the patients presenting minor differences from the
protocol. During analysis, the study groups will be ano-
nymised in order to minimize biased reporting.
The baseline variables among the different groups will be
compared to test the homogeneity produced by random
allocation, in terms of the differences of means and pro-BMC Complementary and Alternative Medicine 2008, 8:12 http://www.biomedcentral.com/1472-6882/8/12
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portions. The magnitude of the difference in the possible
unbalancing produced by the random allocation among
the groups will be evaluated using ratios of means and
proportions (using that of the sham group as the reference
level), and the final fit will be calculated by secondary
analyses with multiple linear regression models. In the
raw analysis (without fitting), significance tests will be
used for the comparisons between k samples (parametric
or not, depending on whether the distribution of the
results variables is asymmetric or otherwise, and on the
homogeneity of their variances), taking the control group
(group C) as the reference level, and using comparison
tests for the differences of the means in the main results
variable (DWM1), both for the intergroup comparisons
(for independent samples) and for the comparisons
between the baseline and the final levels for each group
(in the latter case, using tests for non-independent or
paired samples).
For the main results variable (DWM1), linear regression
models will be constructed, adjusted for the baseline level
and analysing per ITT. The group variables will be
included, taking the control group as a reference, together
with the sociodemographic variables (age and sex) and
the baseline variables of the severity of the complaint
(pain intensity and frequency). We will adjust for possible
confounders using criteria of statistical significance and of
confusion. The detection of possible interactions with the
treatment group variable will be evaluated by criteria of
statistical significance for the corresponding interaction
terms. The level of significance will be established at α <
0.05. The model will be reconstructed, removing all the
observations with Cook's distances above the 90th percen-
tile of the distribution, in order to test the consistency of
the results obtained.
It is our intention to perform an economic analysis from
the standpoint of the Andalusia Public Health Service.
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